Quarterly report pursuant to Section 13 or 15(d)

Share-based Compensation

v3.23.3
Share-based Compensation
9 Months Ended
Jun. 30, 2023
Share-based Compensation [Abstract]  
Share-based Compensation Note 10 – Share-based Compensation

We allocate share-based compensation expense to cost of sales, selling, general and administrative expense, and research and development expense based on the award holder’s employment function. For the three and nine months ended June 30, 2023 and 2022, we recorded share-based compensation expenses as follows:

Three Months Ended

Nine Months Ended

June 30,

June 30,

2023

2022

2023

2022

Cost of sales

$

112,515

$

25,275

$

263,879

$

70,923

Selling, general and administrative

3,667,599

2,052,755

10,183,510

5,036,356

Research and development

770,718

832,946

2,786,310

1,809,066

Share-based compensation

$

4,550,832

$

2,910,976

$

13,233,699

$

6,916,345

We have issued share-based awards to employees and non-executive directors under the Company’s approved equity plans. Upon the exercise of share-based awards, new shares are issued from authorized common stock.

Equity Plans

In June 2022, the Company’s board of directors adopted the Company’s 2022 Employment Inducement Equity Incentive Plan (the “Inducement Plan”). The Inducement Plan is a non-shareholder approved stock plan adopted pursuant to the “inducement exception” provided under Nasdaq listing rules. The Inducement Plan is used exclusively for the issuance of equity awards to certain new hires who satisfied the requirements to be granted inducement grants under Nasdaq rules as an inducement material to the individual’s entry into employment with the Company. The Company reserved 4,000,000 shares of common stock under the Inducement Plan and as of June 30, 2023, 3,895,250 shares remain available for issuance under the Inducement Plan.

In March 2018, the Company’s stockholders approved the Company's 2018 Equity Incentive Plan (as amended, the “2018 Plan”). On March 29, 2022, the Company’s stockholders approved an increase in the number of shares that may be issued under the 2018 Plan to 18.5 million. As of June 30, 2023, 2,431,616 shares remain available for issuance under the 2018 Plan.

In July 2017, the Company’s stockholders approved the Company's 2017 Equity Incentive Plan (the “2017 Plan”). A total of 4.7 million shares are authorized for issuance under the 2017 Plan. As of June 30, 2023, 12,472 shares remain available for issuance under the 2017 Plan. The 2017 Plan replaced the Company's 2008 Stock Incentive Plan (the “2008 Plan”), and no further awards will be made under the 2008 Plan.

Stock Options

Each option grants the holder the right to purchase from us one share of our common stock at a specified price, which is generally the closing price per share of our common stock on the date the option is issued. Options generally vest on a pro-rata basis on each anniversary of the issuance date within three years of the date the option is issued. Options may be exercised after they have vested and prior to the specified expiry date provided applicable exercise conditions are met, if any. The expiry date can be for periods of up to ten years from the date the option is issued. The fair value of each option is estimated on the date of grant using the Black-Scholes option pricing model based on the assumptions established at that time. The Company accounts for forfeitures as they occur and does not estimate forfeitures as of the option grant date. The Company recognized a reduction in share-based compensation expense of $317,000 and $1.8 million during the three and nine months ended June 30, 2023 for stock options forfeited during the period. The reduction in share-based compensation expense during the three and nine months ended June 30, 2022 for stock options forfeited was immaterial.

The following table outlines the weighted average assumptions for options granted during the three and nine months ended June 30, 2023 and 2022:

Three Months Ended

Nine Months Ended

June 30,

June 30,

2023

2022

2023

2022

Weighted Average Assumptions:

Expected volatility

104.96%

92.58%

101.37%

83.77%

Expected dividend yield

0.00%

0.00%

0.00%

0.00%

Risk-free interest rate

3.51%

3.01%

3.92%

2.10%

Expected term (in years)

6.0

6.0

6.0

6.0

Fair value of options granted

$

1.12

$

8.97

$

5.55

$

6.92

During the three and nine months ended June 30, 2023 and 2022, the Company used historical volatility of our common stock over a period equal to the expected life of the options to estimate their fair value. The dividend yield assumption is based on the Company’s recent history and expectation of future dividend payouts on the common stock. The risk-free interest rate is based on the implied yield available on U.S. treasury zero-coupon issues with an equivalent remaining term.

The following table summarizes the stock options outstanding and exercisable at June 30, 2023:

Weighted Average

Remaining

Aggregate

Number of

Exercise Price

Contractual Term

Intrinsic

Shares

Per Share

(years)

Value

Outstanding at September 30, 2022

14,263,470

$

5.00

Granted

4,927,775

$

6.93

Exercised

(148,125)

$

2.27

Forfeited and expired

(1,078,262)

$

11.00

Outstanding at June 30, 2023

17,964,858

$

5.19

7.19

$

35,604

Exercisable at June 30, 2023

10,213,653

$

3.43

5.77

$

34,604

The aggregate intrinsic values in the table above are before income taxes and represent the number of in-the-money options outstanding or exercisable multiplied by the closing price per share of the Company’s common stock on the last trading day of the quarter ended June 30, 2023 of $1.19, less the respective weighted average exercise price per share at period end.

The total intrinsic value of options exercised during the nine months ended June 30, 2023 and 2022 was approximately $486,000 and $1.3 million, respectively. Cash received from options exercised during the nine months ended June 30, 2023 and 2022 was approximately $337,000 and $411,000, respectively.

As of June 30, 2023, the Company had unrecognized compensation expense of approximately $34.8 million related to unvested stock options. This expense is expected to be recognized over a weighted average period of 2.1 years.

Stock Appreciation Rights

In connection with the closing of our acquisition of Aspen Park Pharmaceuticals, Inc. on October 31, 2016 (the “APP Acquisition”), the Company issued stock appreciation rights based on 50,000 and 140,000 shares of the Company’s common stock to an employee and an outside director, respectively, that vested on October 31, 2018. The stock appreciation rights have a ten-year term and an exercise price per share of $0.95, which was the closing price per share of the Company’s common stock as quoted on Nasdaq on the trading day immediately preceding the date of the completion of the APP Acquisition. Upon exercise, the stock appreciation rights will be settled in common stock issued under the 2017 Plan. As of June 30, 2023, vested stock appreciation rights based on 50,000 shares of common stock remain outstanding.